105 related articles for article (PubMed ID: 16907691)
1. A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics.
Farahani P; Levine M; Goeree R
J Eval Clin Pract; 2006 Aug; 12(4):463-70. PubMed ID: 16907691
[TBL] [Abstract][Full Text] [Related]
2. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
[TBL] [Abstract][Full Text] [Related]
3. An economic approach to health care.
Homik JE; Suarez-Almazor M
Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
[TBL] [Abstract][Full Text] [Related]
4. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
Farahani P; Levine M; Gaebel K; Thabane L
Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
Kobelt G; Lindgren P; Singh A; Klareskog L
Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
Feldman AM; de Lissovoy G; Bristow MR; Saxon LA; De Marco T; Kass DA; Boehmer J; Singh S; Whellan DJ; Carson P; Boscoe A; Baker TM; Gunderman MR
J Am Coll Cardiol; 2005 Dec; 46(12):2311-21. PubMed ID: 16360064
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
[TBL] [Abstract][Full Text] [Related]
8. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.
Kobelt G; Lekander I; Lang A; Raffeiner B; Botsios C; Geborek P
Int J Technol Assess Health Care; 2011 Jul; 27(3):193-200. PubMed ID: 21736857
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of psoriasis therapy with etanercept in Germany.
Heinen-Kammerer T; Daniel D; Stratmann L; Rychlik R; Boehncke WH
J Dtsch Dermatol Ges; 2007 Sep; 5(9):762-8. PubMed ID: 17760896
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based medicine and cost-effectiveness.
Brown GC; Sharma S; Brown MM; Garrett S
J Health Care Finance; 1999; 26(2):14-23. PubMed ID: 10605659
[TBL] [Abstract][Full Text] [Related]
12. The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.
Lekander I; Kobelt G; Svarvar P; Ljung T; van Vollenhoven R; Borgström F
Value Health; 2013; 16(2):251-8. PubMed ID: 23538176
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of group psychotherapy for depression in Uganda.
Siskind D; Baingana F; Kim J
J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness as an outcome in randomized clinical trials.
Hlatky MA; Owens DK; Sanders GD
Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness and cost-utility study of lung transplantation.
Vasiliadis HM; Collet JP; Penrod JR; Ferraro P; Poirier C
J Heart Lung Transplant; 2005 Sep; 24(9):1275-83. PubMed ID: 16143245
[TBL] [Abstract][Full Text] [Related]
18. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
Roe RH; Lass JH; Brown GC; Brown MM
Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
Henriksson M; Epstein DM; Palmer SJ; Sculpher MJ; Clayton TC; Pocock SJ; Henderson RA; Buxton MJ; Fox KA
Heart; 2008 Jun; 94(6):717-23. PubMed ID: 18032459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
